Journal of Vascular Surgery
Volume 47, Issue 5 , Pages 1033-1038 , May 2008

Endogenous heparin activity is decreased in peripheral arterial occlusive disease

  • Venugopal K. Shankar, FRCS(Ed)

      Affiliations

    • Corresponding Author InformationReprint requests: V. K. Shankar, University of Oxford, Nuffield Department of Surgery, Level 6, John Radcliffe Hospital, Headley Way, Headington, Oxford OX3 9DU, UK.
    • ,
  • Ashok Handa, FRCS(Eng)
    • ,
  • Linda Hands, MS, FRCS

Received 20 May 2007 ,Accepted 12 November 2007.

References 

  1. Enerback L, Kolset SO, Kusche M, Hjerpe A, Lindahl U. Glycosaminoglycans in rat mucosal mast cells. Biochem J. 1985;227:661–668
  2. Mertens G, Cassiman JJ, Van den Berghe H, Vermylen J, David G. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells (Core protein characterization and antithrombin III binding properties). J Biol Chem. 1992;267:20435–20443
  3. Justus AC, Roussev R, Norcross JL, Faulk WP. Antithrombin binding by human umbilical vein endothelial cells: effects of exogenous heparin. Thromb Res. 1995;79:175–186
  4. Staprans I, Felts JM. Isolation and characterisation of glycosaminoglycans in human plasma. J Clin Invest. 1985;76:1984–1991
  5. Cavari S, Stramaccia L, Vannucchi S. Endogenous heparinase-sensitive anticoagulant activity in human plasma. Thromb Res. 1992;67:157–165
  6. Al-Hakim A, Linhardt RJ. Electrophoresis and detection of nanogram quantities of exogenous and endogenous glycosaminoglycans in biological fluids. Appl Theor Electrophor. 1991;1:305–312
  7. Volpi N, Cusmano M, Venturelli T. Qualitative and quantitative studies of heparin and chondroitin sulfates in normal human plasma. Biochim Biophys Acta. 1995;1243:49–58
  8. Nielsen VG. Endogenous heparin decreases the thrombotic response to hemorrhagic shock in rabbits. J Crit Care. 2001;16:64–68
  9. Montalto P, Vlachogiannakos J, Cox DJ, Pastacaldi S, Patch D, Burroughs AK. Bacterial infection in cirrhosis impairs coagulation by a heparin effect: a prospective study. J Hepatol. 2002;37:463–470
  10. Cornillon B, Mazzorana M, Dureau G, Belleville J. Characterization of a heparin-like activity released in dogs during deep hypothermia. Eur J Clin Invest. 1988;18:460–464
  11. Kettner SC, Gonano C, Seebach F, Sitzwohl C, Acimovic S, Stark J, et al. Endogenous heparin-like substances significantly impair coagulation in patients undergoing orthotopic liver transplantation. Anesth Analg. 1998;86:691–695
  12. Fareed J, Walenga JM, Hoppensteadt DA, Messmore HL. Studies on the profibrinolytic actions of heparin and its fractions. Semin Thromb Hemost. 1985;11:199–207
  13. Blajchman MA, Young E, Ofosu FA. Effects of unfractionated heparin, dermatan sulphate and low molecular heparin on vessel wall permeability in rabbits. Ann N Y Acad Sci. 1989;556:245–254
  14. Koksch M, Zeiger F, Wittig K, Pfeiffer D, Ruehlmann C. Haemostatic derangement in advanced peripheral occlusive arterial disease. Int Angiol. 1999;18:256–262
  15. Engelberg H. Low-dose intermittent heparin therapy decreases plasma fibrinogen levels. Semin Thromb Hemost. 1991;17(suppl 2):219–223
  16. Andreozzi GM, Signorelli SS, Cacciaguerra G, Di Pino L, Martini R, Monaco S, et al. Three-month therapy with calcium-heparin in comparison with ticlopidine in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class. Angiology. 1993;44:307–313
  17. Calabro A, Piarulli F, Milan D, Rossi A, Coscetti G, Crepaldi G. Clinical assessment of low molecular weight heparin effects in peripheral vascular disease. Angiology. 1993;44:188–195
  18. Mallett SV, Cox DJ. Thrombelastography. Br J Anaesth. 1992;69:307–313
  19. Tuman KJ, Spiess BD, McCarthy RJ, Ivankovich AD. Comparison of viscoelastic measures of coagulation after cardiopulmonary bypass. Anesth Analg. 1989;69:69–75
  20. Cohen E, Caprini J, Zuckerman L, Vagher P, Robinson B. Evaluation of three methods used to identify accelerated coagulability. Thromb Res. 1977;10:587–604
  21. Spiess BD, Wall MH, Gillies BS, Fitch JC, Soltow LO, Chandler WL. A comparison of thromboelastography with heparinase or protamine sulfate added in vitro during heparinized cardiopulmonary bypass. Thromb Haemost. 1997;78:820–826
  22. Nielsen VG. The detection of changes in heparin activity in the rabbit: a comparison of anti-xa activity, thrombelastography, activated partial thromboplastin time, and activated coagulation time. Anesth Analg. 2002;95:1503–1506
  23. Tuman KJ, McCarthy RJ, Djuric M, Rizzo V, Ivankovich AD. Evaluation of coagulation during cardiopulmonary bypass with a heparinase-modified thromboelastographic assay. J Cardiothorac Vasc Anesth. 1994;8:144–149
  24. Shankar VK, Chaudhury SR, Uthappa MC, Handa A, Hands LJ. Changes in blood coagulability as it traverses the ischemic limb. J Vasc Surg. 2004;39:1033–1042
  25. Camenzind V, Bombeli T, Seifert B, Jamnicki M, Popovic D, Pasch T, et al. Citrate storage affects Thrombelastograph analysis. Anesthesiology. 2000;92:1242–1249
  26. Mallett SV, Cox DJ. Thromboelastography. Br J Anaesth. 1992;69:307–313
  27. Murata K, Yokoyama Y. Acidic glycosaminoglycan, lipid and water contents in human coronary arterial branches. Atherosclerosis. 1982;45:53–65
  28. Stary HC, Blankenhorn DH, Chandler AB, Glagov S, Insull W, Richardson M, et al. A definition of the intima of human arteries and of its atherosclerosis-prone regions (A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Association). Circulation. 1992;85:391–405
  29. Simionescu M, Simionescu N. Functions of the endothelial cell surface. Annu Rev Physiol. 1986;48:279–293
  30. Marcum JA, Rosenberg RD. Role of endothelial cell surface heparin-like polysaccharides. Ann N Y Acad Sci. 1989;556:81–94
  31. Pillarisetti S, Paka L, Obunike JC, Berglund L, Goldberg IJ. Subendothelial retention of lipoprotein (a) (Evidence that reduced heparan sulfate promotes lipoprotein binding to subendothelial matrix). J Clin Invest. 1997;100:867–874
  32. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. J Am Coll Cardiol. 2003;41(4 suppl S):7S–14S
  33. Hawiger J. Formation and regulation of platelet and fibrin hemostatic plug. Hum Pathol. 1987;18:111–122
  34. Sternbergh WC, Makhoul RG, Adelman B. Heparin prevents postischemic endothelial cell dysfunction by a mechanism independent of its anticoagulant activity. J Vasc Surg. 1993;17:318–327
  35. Reininger CB, Graf J, Reininger AJ, Spannagl M, Steckmeier B, Schweiberer L. Increased platelet and coagulatory activity in peripheral atherosclerosis flow mediated platelet function is a sensitive and specific disease indicator. IntAngiol. 1996;15:335–343
  36. O'Brien JR. Shear-induced platelet aggregation. Lancet. 1990;335:711–713
  37. Brevetti G, Silvestro A, Di Giacomo S, Bucur R, Di Donato A, Schiano V, et al. Endothelial dysfunction in peripheral arterial disease is related to increase in plasma markers of inflammation and severity of peripheral circulatory impairment but not to classic risk factors and atherosclerotic burden. J Vas Surg. 2003;38:374–379
  38. Mannarino E, Pasqualini L, Innocente S, Orlandi U, Scricciolo V, Lombardini R, et al. Efficacy of low-molecular-weight heparin in the management of intermittent claudication. Angiology. 1991;42:1–7
  39. Varty K, Allen KE, Jones L, Sayers RD, Ratliff DA, Bell PR, et al. The influence of low molecular weight heparin on neointimal proliferation in cultured human saphenous vein. Eur J Vasc Surg. 1994;8:174–178
  40. Koppensteiner R, Sprins S, Amann-Vesti BR, Meier T, Pfammatter T, Rousson V, et al. Low-molecular- weight heparin for prevention of restenosis after femoropopliteal percutaneous transluminal angioplasty: a randomized controlled trial. J Vasc Surg. 2006;44:1247–1253

 Competition of interest: none.

PII: S0741-5214(07)01783-1

doi: 10.1016/j.jvs.2007.11.030

Journal of Vascular Surgery
Volume 47, Issue 5 , Pages 1033-1038 , May 2008

Article Tools

* Image Usage & Resolution